A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a chinese population

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3633-3640

  Zhang, Zhengdong ^a   Wang, Meilin ^a   Zhang, Zhizhong ^a   Zhu, Haixia ^a   Fu, Guangbo ^a   Wang, Shouyu ^a   Wu, Dongmei ^a   Zhou, Jianwei ^a   Wei, Qingyi ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTOSINE; GUANINE; MESSENGER RNA; PROTEIN MDM2; CCAAT ENHANCER BINDING PROTEIN; MDM2 PROTEIN, HUMAN; TUMOR MARKER;

ALLELE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BLADDER CANCER; CANCER CELL CULTURE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MDM2 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN; BLADDER TUMOR; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; POLYMERASE CHAIN REACTION; RISK FACTOR; WESTERN BLOTTING;

ASIAN CONTINENTAL ANCESTRY GROUP; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CCAAT-ENHANCER-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 50349103246     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5155     Document Type: Article

References (31)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
2. Olivier M. Hussain SP, Caron de Fromentel C. Hainaut P, Harris CC. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004;157:247-70.
3. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993:12:461-8.
4. Montes de Oca Luna R, Wagner DS. Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995:378:203-6.
5. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002:12:53-9.
6. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003;1:993-1000.
7. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 1994;8:1739-49.
8. Zauberman A, Flusberg D, HauptY, BarakY, Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 1995:23:2584-92.
9. Liang H, Lunec J. Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene. Gene 2005;361:112-8.
10. MomandJ, Jung D, Wilczynski S. Niland J. The MDM2 gene amplification database. Nucleic Acids Res1998;26:3453-9.
11. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
12. Hainaut P, Pfeifer GP. Patterns of p53 G→Ttransver-sions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-74.
13. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
14. Onat OE.Tez M, OzcelikT, Toruner GA. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 2006:26:3473-5.
15. Sanchez-Carbayo M, Socci ND, Kirchoff T, et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors,TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 2007;13:3215-20.
16. Gabriel SB, SchaffnerSF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
17. Stram DO. Software for tag single nucleotide polymorphism selection. Hum Genomics 2005;2: 144-51.
18. Couzin J. Genomics. The HapMap gold rush: researchers mine a rich deposit. Science 2006;312: 1131.
19. Li C.WuW, Liu J. et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 2006:16:245-51.
20. Goddard KA, Hopkins PJ, Hall JM.WitteJS. Linkage disequilibrium and allele-frequency distributions for 114 single-nucleotide polymorphisms in five populations. Am J Hum Genet 2000:66:216-34.
21. Sun X, Stephens JC, Zhao H. The impact of sample size and marker selection on the study of haplotype structures. Hum Genomics 2004;1:179-93.
22. Stram DO, Haiman CA, Hirschhorn JN, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003:55:27-36.
23. Schuster MB. Porse BT. C/EBPα: a tumour suppressor in multiple tissues? Biochim Biophys Acta 2006: 1766:88-103.
24. 24.WacholderS, ChanockS, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
25. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
26. Oliner JD, Kinzler KW, Meltzer PS. George DL. Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
27. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G H.A. Clowes Memorial Award Lecture. Cancer Res 1999:59:1-7.
28. Schmitz-Drager BJ, Kushima M, Goebell P. et al. p53 and MDM2 in the development and progression of bladder cancer. Eur Urol 1997;32:487-93.
29. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent rote for Mdm2 in tu-morigenesis. Proc Natl Acad Sci U S A 1998:95 15608-12.
30. Lundgren K, Montes de Oca Luna R, McNeill YB, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997,11: 714-25.
31. Michael D, Oren M. The p53-2 module and the ubiquitin system. Semin Cancer Biol 2003. 13:49-58.